Nordea sees strong Danish biotech sector
Pharmaceutical sector analyst Michael Novod from Nordea sees great potential in a number of Danish biotech companies that have matured significantly in the last 15 years. In three to five years it will be seen whether or not they have succeeded.
by Henrik Tüchsen
The last 15 years have seen a significant maturation of Danish biotech which is in a very strong position given the size of the country, and with great potential in a number of the companies that are still standing.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab CEO: Important data on the horizon
For abonnenter
International biotech is in great shape
For abonnenter
